Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033384 · ClinicalTrials.gov registry record · Phase 2
CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00033384: Completed Phase 2 study, sponsored by University of Alabama at Birmingham.
NCT00033384 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033384, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of CI-1040 in treating patients who have metastatic or unresectable breast, colon, pancreatic, or non-small cell lung cancer.
Interventions
- DRUG CI-1040
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-02 |
| Est. Completion | 2003-11 |
| Phase | Phase 2 |
What the finished NCT00033384 record still lists
NCT00033384 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which CI-1040 is the first listed.
NCT00033384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00033384 about?
NCT00033384 is a clinical study titled "CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer". RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of CI-1040 in treating patients who have metastatic or unresectable breast, colon, pancreatic, or non...
What is the current status of trial NCT00033384?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-02. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00033384?
The interventions under investigation include: CI-1040 (DRUG).
Who is sponsoring clinical trial NCT00033384?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia